Literature DB >> 15830008

High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation.

C Shimazaki, R Uchida, S Nakano, K Namura, S-i Fuchida, A Okano, M Okamoto, T Inaba.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15830008     DOI： 10.1038/sj.leu.2403758

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

Review 1.  Proteasome inhibitors and bone disease.

Authors:  Ya-Wei Qiang; Christoph J Heuck; John D Shaughnessy; Bart Barlogie; Joshua Epstein
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

2.  Targeting bone as a therapy for myeloma.

Authors:  Ping Wu; Gareth J Morgan
Journal:  Cancer Microenviron       Date:  2011-08-11

3.  Dexamethasone reduces the risk of bortezomib-induced pulmonary complications in Japanese myeloma patients.

Authors:  Chihiro Shimazaki; Yutaka Kobayashi; Tohru Inaba; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2006-07       Impact factor: 2.490

Review 4.  Tumor-host cell interactions in the bone disease of myeloma.

Authors:  Jessica A Fowler; Claire M Edwards; Peter I Croucher
Journal:  Bone       Date:  2010-07-13       Impact factor: 4.398

5.  Soluble molecules and bone metabolism in multiple myeloma: a review.

Authors:  Gabriele Zoppoli; Enrico Balleari; Riccardo Ghio
Journal:  Clin Cases Miner Bone Metab       Date:  2008-01

6.  A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.

Authors:  Marci D Jones; Julie C Liu; Thomas K Barthel; Sadiq Hussain; Erik Lovria; Dengfeng Cheng; Jesse A Schoonmaker; Sudhanshu Mulay; David C Ayers; Mary L Bouxsein; Gary S Stein; Siddhartha Mukherjee; Jane B Lian
Journal:  Clin Cancer Res       Date:  2010-09-15       Impact factor: 12.531

7.  Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma.

Authors:  Shuji Ozaki; Osamu Tanaka; Shiro Fujii; Yuri Shigekiyo; Hirokazu Miki; Masahito Choraku; Kumiko Kagawa; Jin Asano; Kyoko Takeuchi; Ken-ichi Kitazoe; Toshihiro Hashimoto; Masahiro Abe; Toshio Matsumoto
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

8.  Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice.

Authors:  Siddhartha Mukherjee; Noopur Raje; Jesse A Schoonmaker; Julie C Liu; Teru Hideshima; Marc N Wein; Dallas C Jones; Sonia Vallet; Mary L Bouxsein; Samantha Pozzi; Shweta Chhetri; Y David Seo; Joshua P Aronson; Chirayu Patel; Mariateresa Fulciniti; Louise E Purton; Laurie H Glimcher; Jane B Lian; Gary Stein; Kenneth C Anderson; David T Scadden
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

Review 9.  The pathogenesis of the bone disease of multiple myeloma.

Authors:  Claire M Edwards; Junling Zhuang; Gregory R Mundy
Journal:  Bone       Date:  2008-02-21       Impact factor: 4.398

Review 10.  New therapies in multiple myeloma.

Authors:  F Merchionne; F Perosa; F Dammacco
Journal:  Clin Exp Med       Date:  2007-10-03       Impact factor: 3.984
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.